isoproterenol has been researched along with Huntington Disease in 3 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "While Huntington's disease (HD) is classified as a neurological disorder, HD patients exhibit a high incidence of cardiovascular events leading to heart failure and death." | 1.43 | Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease. ( Colwell, CS; Coppola, G; Fishbein, MC; Gao, F; Ghiani, CA; Jordan, MC; Park, S; Roos, KP; Schroeder, AM; Wang, HB, 2016) |
| "wasting) in Huntington's disease (HD), we examined adipocytes in a transgenic model of HD, the R6/2 mouse." | 1.31 | Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. ( Del Mar , NA; Fain, JN; Goldowitz, D; Meade, CA; Reiner, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mielcarek, M | 1 |
| Bondulich, MK | 1 |
| Inuabasi, L | 1 |
| Franklin, SA | 1 |
| Muller, T | 1 |
| Bates, GP | 1 |
| Schroeder, AM | 1 |
| Wang, HB | 1 |
| Park, S | 1 |
| Jordan, MC | 1 |
| Gao, F | 1 |
| Coppola, G | 1 |
| Fishbein, MC | 1 |
| Roos, KP | 1 |
| Ghiani, CA | 1 |
| Colwell, CS | 1 |
| Fain, JN | 1 |
| Del Mar , NA | 1 |
| Meade, CA | 1 |
| Reiner, A | 1 |
| Goldowitz, D | 1 |
3 other studies available for isoproterenol and Huntington Disease
| Article | Year |
|---|---|
The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model.
Topics: Adrenergic beta-Antagonists; Animals; Brain-Derived Neurotrophic Factor; Cardiomyopathies; Collagen | 2014 |
Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease.
Topics: Adrenergic beta-Agonists; Aging; Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Fibrosis; | 2016 |
Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation.
Topics: Adipocytes; Adipose Tissue; Adrenergic beta-Agonists; Animals; Blood Glucose; Culture Techniques; De | 2001 |